Search
Feed aggregator
Avenzo Closes $150M Oversubscribed Series A-1 to Advance Cancer Therapies
Avenzo Closes $150M Oversubscribed Series A-1 to Advance Cancer Therapies 3/27/2024
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData 3/27/2024
Bayer’s Sweeping Executive Cuts, Wegovy’s Expanding Reach
Bayer’s Sweeping Executive Cuts, Wegovy’s Expanding Reach 3/27/2024
Global Healthcare Celebrates Tech Successes & Grapples with Cybersecurity at HIMSS 2024
Global Healthcare Celebrates Tech Successes & Grapples with Cybersecurity at HIMSS 2024 3/27/2024
Analysts Predict Slower Rollout but Ultimate Victory for Casgevy in Race with Lyfgenia
Analysts Predict Slower Rollout but Ultimate Victory for Casgevy in Race with Lyfgenia 3/27/2024
C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More
C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More 3/27/2024
Opinion: Biopharma Should Prioritize Research on the Economics of Therapies
Opinion: Biopharma Should Prioritize Research on the Economics of Therapies 3/27/2024
In an Evolving Market, HR Leaders Balance Business Needs with Employee Engagement
In an Evolving Market, HR Leaders Balance Business Needs with Employee Engagement 3/27/2024
Global study could change how children with multiple sclerosis are treated
A ground-breaking study - the largest of its kind globally - has found children with multiple sclerosis (MS) have better outcomes if treated early and with the same high-efficacy therapies as adults.
There are a limited number of therapies approved for children with MS, with only one considered to be of high-efficacy - meaning highly effective.
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension 3/26/2024
Viking Touts Promising Phase I Data for Weight-Loss Pill Candidate
Viking Touts Promising Phase I Data for Weight-Loss Pill Candidate 3/26/2024
Brazil and Caring Cross to Produce Affordable CAR-T, Stem Cell Gene Therapies
Brazil and Caring Cross to Produce Affordable CAR-T, Stem Cell Gene Therapies 3/26/2024
AstraZeneca’s Ultomiris Wins FDA Approval for Rare Autoimmune Disease
AstraZeneca’s Ultomiris Wins FDA Approval for Rare Autoimmune Disease 3/26/2024
Stoke’s Early-Stage Data for Genetic Epilepsy Drug Sends Stock Skyrocketing
Stoke’s Early-Stage Data for Genetic Epilepsy Drug Sends Stock Skyrocketing 3/26/2024
Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy
Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy 3/26/2024
BioNTech Hit with NIH Notice of Default Over COVID-19 Vaccine Royalties
BioNTech Hit with NIH Notice of Default Over COVID-19 Vaccine Royalties 3/26/2024
FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma 3/25/2024
Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease
Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease 3/25/2024
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline 3/25/2024
World Pharma News
- U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- Researchers publish final results of key clinical trial for gene therapy for sickle cell disease
- Optimal timing maximises Paxlovid benefits for treating COVID-19
- European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options